|
Descriptive statistics by tumor subtypes in the Swedish cohort |
||||||
| Characteristic |
Basal-like |
ERBB2 |
Luminal A |
Luminal B |
Normal-like |
p |
| n = 59 |
n = 43 |
n = 122 |
n = 54 |
n = 91 |
||
|
|
||||||
| Cohort (n) |
0.51e |
|||||
| Stockholm |
25 |
15 |
39 |
23 |
37 |
|
| Uppsala |
34 |
28 |
83 |
31 |
54 |
|
| Mean age at breast cancer diagnosis |
54 |
59 |
66 |
61 |
59 |
<0.001e |
| Menopausal status (%) |
0.0807e |
|||||
| Premenopausal |
27.5 |
13.3 |
10.9 |
24.4 |
18.6 |
|
| Postmenopausal |
72.5 |
86.7 |
89.1 |
75.6 |
78.6 |
|
| Mean tumor size (mm) |
22.9 |
27.9 |
21.8 |
22.6 |
20.7 |
0.0345f |
| Tumor size < 21 mm (%) |
51 |
35 |
57 |
42 |
70 |
<0.001e |
| Elston grade |
<0.001e |
|||||
| I |
3.5 |
4.8 |
34.5 |
5.7 |
43.2 |
|
| II |
21.1 |
38.1 |
54.3 |
39.6 |
52.3 |
|
| III |
75.4 |
57.1 |
11.2 |
54.7 |
4.5 |
|
| p53 mutation (%)a |
64.7 |
39.3 |
9.6 |
38.7 |
3.7 |
<0.001e |
| HRT (%)b |
<0.001e |
|||||
| Never |
60.0 |
78.6 |
81.6 |
82.6 |
48.6 |
|
| Former |
8.0 |
7.1 |
13.2 |
8.7 |
0.0 |
|
| Ongoing |
32.0 |
14.3 |
5.3 |
8.7 |
51.4 |
|
| Lymph-positive (%) |
29 |
48 |
33 |
41 |
33 |
0.312e |
| Estrogen receptor positive (%) |
45.8 |
67.4 |
97.5 |
87.0 |
92.3 |
<0.001e |
| Progesterone receptor positive (%) |
54.2 |
72.1 |
93.2 |
77.8 |
92.3 |
<0.001e |
| Genomically unstable (%)b |
76.0 |
78.6 |
56.4 |
78.3 |
37.1 |
0.0031e |
| Genomic instability by ploidyb |
0.0123e |
|||||
| Diploid stable |
12.0 |
7.1 |
25.6 |
4.3 |
40.0 |
|
| Diploid unstable |
4.0 |
0.0 |
20.5 |
26.1 |
17.1 |
|
| Tetraploid stable |
4.0 |
7.1 |
7.7 |
8.7 |
8.6 |
|
| Tetraploid unstable |
16.0 |
7.1 |
12.8 |
13.0 |
0.0 |
|
| Aneuploid stable |
8.0 |
7.1 |
10.3 |
8.7 |
14.3 |
|
| Aneuploid unstable |
56.0 |
71.4 |
23.1 |
39.1 |
20.0 |
|
| Treatment type (%)c |
0.0353e |
|||||
| None |
39.7 |
35.7 |
43.3 |
35.8 |
46.2 |
|
| Endocrine |
36.2 |
45.2 |
50.8 |
56.6 |
44.0 |
|
| Chemotherapy |
15.5 |
16.7 |
5.0 |
5.7 |
7.7 |
|
| Radiotherapy |
8.6 |
2.4 |
0.8 |
1.9 |
2.2 |
|
| Breast cancer event within 5 years (%)d |
30 |
51 |
17 |
43 |
19 |
<0.001e |
|
ap53 data were available only for the Uppsala cohort. bHRT and genomic instability were available only for the Stockholm cohort. cFor the Stockholm cohort, endocrine comprises endocrine treatment alone and with any other combination. Chemotherapy refers to chemotherapy alone or associated with radiotherapy. Radiotherapy means radiotherapy alone. dBreast cancer event refers to relapse or death for breast cancer. ePearson χ2 test. fAnalysis of variance test. | ||||||
Calza et al. Breast Cancer Research 2006 8:R34 doi:10.1186/bcr1517 |
||||||